Transcript REVEAL Boston April 3 2012 Final Standings

Please pick up your
Audience Response
Keypad in the back of
the room
Audience Response
Questions
Using Your Keypad
• Questions will be displayed along
with the possible answers
• When the countdown clock appears,
press and release the button that best
represents your answer
• Your last answer will be recorded
• Speed and accuracy count
• There is no need to press “GO” or “?”
• Please turn in the keypad before you
leave for the day.
Question # 1
The major goal of HPS3-TIMI 55/REVEAL
is to determine if anacetrapib:
a) Raises HDL
b) Reduces the size of
coronary plaques
c) Reduces the
composite endpoint of
coronary death, MI, or
coronary
revascularization
68%
32%
0%
a)
b)
c)
Question # 2
Anacetrapib works by:
80%
a) Reducing hepatic
cholesterol synthesis
b) Inhibiting cholesteryl
ester transfer protein
c) Reducing absorption
of cholesterol
18%
2%
a)
b)
c)
Question # 3
Which type of patient history below
would NOT be eligible for REVEAL?
A. History of prior PCI for
angina
B. History of myocardial
infarction
C. History of stroke
D. History of peripheral
arterial bypass surgery
E. History of diabetes
mellitus and prior PCI
85%
6%
9%
0%
0%
A.
B.
C.
D.
E.
Question # 4
Which of the following patients would
NOT be eligible?
100%
a) 50 M with prior MI
b) 85 M with prior MI
c) 65 M with diabetes and
a prior PCI
d) 45 F with diabetes, prior
MI, and prior stroke
0%
a)
0%
b)
0%
c)
d)
Question # 5
A subject should be EXCLUDED from
REVEAL if:
100%
a) PCI is planned in the
next 6 months
b) If they require dialysis
c) If they had a history of
rhabdomyolysis following
statin treatment
d) Any of the above
0%
a)
0%
b)
0%
c)
d)
Question # 6
Anacetrapib’s effects include all
EXCEPT?
96%
a) Raising HDL
b) Lowering LDL
c) Raising blood pressure
0%
a)
4%
b)
c)
Let’s Check the
Standings…
Participant Leader Board
579.03
Participant 1C8658
562.61
562.23
554.59
542
Participant C4E88
Participant 1C853C
Participant 15DB4C
Participant 15E5B5
536.83
525.57
508.13
Participant 8360B
Participant C4E03
Participant 15DB8E
500
500
Participant 169D06
Participant C4EE2
Question # 7
The most effective way to monitor and
prevent for possible myositis/
rhabdomyolysis symptoms:
a) Measure CPK
periodically
b) Carefully monitor
symptoms of muscle
aches
c) Review concomitant
medications for excluded
medications
d) All of the above
92%
2%
a)
4%
b)
2%
c)
d)
Question # 8
What procedures are NOT done at the
Screening visit?
a) Confirm eligibility
b) Informed consent
c) Blood pressure and
blood tests
d) Randomization to
anacetrapib or
placebo
98%
0%
a)
0%
b)
2%
c)
d)
Question # 9
Which of the following malignancies is an
EXCLUSION criterion at screening:
a) Surgery for colon cancer 7 years
ago. No evidence of recurrence
b) Basal cell carcinoma 3 years
ago.
c) Hysterectomy for endometrial
cancer 10 years ago. No evidence
of recurrence.
d) Hysterectomy for endometrial
cancer 3 years ago. No evidence
of recurrence.
76%
20%
4%
a)
0%
b)
c)
d)
Question # 10
What Procedures are done at the
Follow-up Visits?
a) Record All SAEs and non-serious
AEs (including asking about
Unexplained muscle pain or
weakness)
b) Assess compliance with study
drug treatment
c) Measure blood pressure and
safety bloods
d) Issue study treatment (7 month
supply)
e) Schedule next follow-up
appointment
f) All of the above
100%
0%
0%
a)
b)
0%
0%
0%
c)
d)
e)
f)
Question # 11
A subject who has been off study drug for 1
year due to prolonged illness would like to
restart the study drug. What should the site
do?
79%
a) Patient can not resume
study drug because they have
been off for >3 months
b) The site should rerandomize the patient
c) The site can restart the
study drug
d) The site should have the
patient re-sign the original
consent form
15%
6%
0%
a)
b)
c)
d)
Question # 12
A patient who is admitted to the hospital
with chest pain, who is found to have
non-cardiac chest pain. Should this be
reported as an SAE?
96%
a) Yes
b) No
4%
a)
b)
Participant Leader Board
1142
Linda Lombardo
1121.2
1100
1099.14
1087.38
Barbara Miller
Angela Anderson
Allison Bohn
Laura Armstrong
1083.97
1077.83
1077.09
Cynthia Tremblay
Sheila Lehmann
Devona Chun-Furlong
1074.59
1070.84
Ann Galla
Antoinette (Toni) Rizzo
Please Return your
Audience Response
Keypad as you leave
the room